Krista Johnson, APRN
Nurse Practitioner · Lexington, KYNPI 1073061768
Payments from drug & device makers
Across 173 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$419
- Abbott$351
- Corcept Therapeutics$299
- Novo Nordisk$268
- Insulet Corporation$204
- Amgen$198
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,18599%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 23 | $419 |
| Abbott | 24 | $351 |
| Corcept Therapeutics | 17 | $299 |
| Novo Nordisk | 14 | $268 |
| Insulet Corporation | 10 | $204 |
| Amgen(2 entities) | 12 | $198 |
| Boehringer Ingelheim | 9 | $157 |
| Dexcom, Inc. | 4 | $145 |
| Antares Pharma, Inc. | 4 | $112 |
| Xeris Pharmaceuticals, Inc. | 5 | $99 |
| Bayer | 5 | $93 |
| Radius Health, Inc. | 4 | $84 |
| AbbVie | 4 | $78 |
| Medtronic | 3 | $74 |
| Recordati_rare_diseases_inc. | 3 | $62 |
| Madrigal Pharmaceuticals | 3 | $51 |
| BETA Bionics, Inc. | 3 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Sequel Med Tech, LLC | 2 | $41 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Ascensia Diabetes Care US Inc. | 2 | $31 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Lifescan, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Sandoz | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| GSK | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Merck | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$3,219 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 362 | $454,239 |
| MounjaroTirzepatide | 218 | $303,641 |
| JardianceEmpagliflozin | 254 | $283,511 |
| Tresiba Flextouch U-100Insulin Degludec | 174 | $159,370 |
| JanuviaSitagliptin Phosphate | 99 | $121,737 |
| TrulicityDulaglutide | 84 | $118,729 |
| FarxigaDapagliflozin Propanediol | 94 | $109,874 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $70,744 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 34 | $62,203 |
| RybelsusSemaglutide | 36 | $56,401 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 287 | $56,378 |
| ForteoTeriparatide | 13 | $53,842 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $53,705 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $50,486 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $46,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $268 | $524,619437 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $419 | $485,802340 claims |
| Boehringer IngelheimJardiance, Tradjenta | $157 | $321,377298 claims |
| MerckJanuvia, Janumet Xr, Janumet | $14 | $182,641162 claims |
| AstraZenecaFarxiga | $15 | $109,87494 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $41 | $46,48724 claims |
| AmgenProlia | $198 | $44,98325 claims |
| Radius Health, Inc.Tymlos | $84 | $34,67113 claims |
| AbbVieSynthroid | $78 | $14,411184 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Lexington
- Rachael BradfordLexington$447K
- Juawanna SchullerLexington$26K
- Jessica SchorckLexington$26K
- Amelia HendricksonLexington$22K
- Megan CollettLexington$13K
- Amy NydamLexington$11K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.